Loading...
•
Sep 30, 2023
CRISPR Therapeutics Q3 2023 Earnings Report
Reported financial results and provided a business update.
Key Takeaways
CRISPR Therapeutics reported its Q3 2023 financial results, showing a net loss of $112.2 million compared to a net loss of $174.5 million for the third quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $1,739.8 million as of September 30, 2023. Significant progress was noted across its clinical pipeline, especially with exa-cel awaiting FDA decision.
Advisory Committee meeting completed for exa-cel for severe sickle cell disease, with a PDUFA target action date of December 8, 2023.
Exa-cel assigned PDUFA target action date of March 30, 2024 for transfusion-dependent beta thalassemia.
Clinical trials are ongoing for CAR T product candidates, CTX110 and CTX112, targeting CD19 in B-cell malignancies.
Phase 1 clinical trial initiated for CTX310, targeting angiopoietin-related protein 3 (ANGPTL3).
Forward Guidance
CRISPR Therapeutics is advancing its pipeline with key milestones expected in the near term, particularly the PDUFA date for exa-cel and the progression of in vivo programs. They are also advancing additional programs utilizing in vivo delivery to address both rare and common diseases.
Positive Outlook
- Potential approval of exa-cel could bring a transformative therapy to patients living with sickle cell disease.
- Advancing multiple in vivo programs directed towards cardiovascular indications and beyond.
- CTX310 and CTX320 have the potential to shift the treatment paradigm for ASCVD with a single-dose, potentially life-long durable editing approach.
- Received a new grant from the Bill & Melinda Gates Foundation to research in vivo gene editing of hematopoietic stem and progenitor cells (HSPCs).
- Advancing additional programs utilizing in vivo delivery to address both rare and common diseases.
Challenges Ahead
- Efficacy and safety results from ongoing clinical trials, including of exa-cel, will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory submissions.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...